However, emerging evidence has suggested that chemotherapy agents, particularly fluoropyrimidines (e.g., 5-fluorouracil, capecitabine) and epidermal growth factor receptor (EGFR) inhibitors (e.g., cetuximab), can induce endothelial dysfunction, thereby increasing the risk of vascular events like dissection [[7], [8], [9],17]. The gene discussed is EGFR; the disease is endothelial dysfunction.